ClinicalTrials.gg
RecruitingNCT07154823AquariusUpdated Oct 9, 2026

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

An observational study in Acute Myeloid Leukaemia (AML) and Follicular Lymphoma ( FL), sponsored by Tempus AI. Recruiting at 13 sites in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Tempus AI · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 9, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
550
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
25th of 126
550 · median 98
Started
2026
with 72 others
Observational
126 of 2,138
29 open now
Primary completion
2034-11
later than 450 of 461 live
Registered
2,071st of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 25th largest by planned enrollment of the 126 observational ones that give a count, is one of 73 that started in 2026, is one of 126 observational ones, reaches primary completion later than 450 of the 461 other live ones, and was the 2,071st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.

03

Conditions studied

  • Acute Myeloid Leukaemia (AML)
  • Follicular Lymphoma ( FL)

Keywords

  • Hematologic Malignancy
  • Acute Myeloid Leukemia
  • AML
  • Next Generation Sequencing
  • NGS
  • Follicular Lymphoma
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study is intended to include multiple hematologic malignancies.

Eligibility criteria

All Cohorts Inclusion Criteria:

  1. Willing and able to participate in the research and provide biospecimens
  2. Willing and able to provide

Cohort 001 Inclusion:

  1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification
  2. Secondary AML is allowed

Cohort 002 Inclusion:

  1. confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
  2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
  3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
  4. 002B (Newly Diagnosed, High Risk): Intended for treatment
  5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the (ULN)
  6. 002C ( High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
  7. 002D (Transformed FL): Pathologically confirmed transformation

All Cohorts Exclusion Criteria:

1. Not willing or able to adhere with the study procedures

Cohort 001:

1. Have received any prior therapy intended for standard of care (SoC) treatment of AML

Cohort 002:

  1. 002A: Received prior treatment for follicular lymphoma
  2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
  3. 002A: Resected patients with NED
  4. 002B: Intended for active observation
  5. 002B: Received prior treatment for follicular lymphoma
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
550 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 001: Newly Diagnosed Acute Myeloid Leukemia (AML)

    Newly diagnosed patients with a primary or secondary diagnosis of Acute Myeloid Leukemia (AML)

    Other: None - Observational Study

  • Cohort 002: Folicular Lymphoma

    Cohort 002 contains four subgroups of Follicular Lymphoma (FL): A: Newly Diagnosed FL on Active Observation; B: Newly Diagnosed High Risk FL; C: Relapsed / Refractory High Risk POD24 FL; D: Transformed FL

    Other: None - Observational Study

Interventions

  • OtherNone - Observational Study

    There are no interventions in this observational study.

06

What researchers measure

Primary outcomes

  1. To assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications.

    The goal of this biomarker discovery registry is to assess DNA and RNA expression patterns and potential biomarkers in biospecimens collected at baseline and throughout treatment, with the goal of generating hypotheses about predictive markers for therapy selection, prognostic indicators, and potential mechanisms of resistance to standard-of-care therapies across multiple hematologic indications.

    Time frame: 5 years

07

Study locations

13 of 13 sites recruiting
08

References and documents

Publications

  • Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PubMed 35797463 ↗
  • Dohner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Lowenberg B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409. PubMed 39133932 ↗
  • Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023 Aug 22;7(16):4371-4380. doi: 10.1182/bloodadvances.2023009681. PubMed 37603349 ↗
  • Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. PubMed 27511158 ↗
  • Reed SC, Croessmann S, Park BH. CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clin Cancer Res. 2023 Apr 14;29(8):1403-1411. doi: 10.1158/1078-0432.CCR-22-2598. PubMed 36454121 ↗
  • Salam DSDA, Thit EE, Teoh SH, Tan SY, Peh SC, Cheah SC. C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases. J Cancer. 2020 Jan 1;11(1):190-198. doi: 10.7150/jca.36954. eCollection 2020. PubMed 31892985 ↗
  • Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016 Sep;13(3):360-372. doi: 10.20892/j.issn.2095-3941.2016.0043. PubMed 27807503 ↗
  • Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2021 Sep 20;39(27):3044-3055. doi: 10.1200/JCO.20.03458. Epub 2021 Jun 22. PubMed 34156874 ↗
  • Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155. doi: 10.1182/asheducation-2016.1.149. PubMed 27913474 ↗
  • Kikushige Y. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. J Clin Exp Hematop. 2020 Dec 15;60(4):146-158. doi: 10.3960/jslrt.20036. Epub 2020 Nov 4. PubMed 33148933 ↗
  • Thomas M. Pharma and the benefits of Real World Data. Drug Discovery World (DDW). Published November 4, 2021. Accessed May 5, 2023. https://www.ddw-online.com/trends-analysis-pharma-and-the-benefits-of-real-world-data-13702-202111/
  • Office of the Commissioner. Oncology Real World Evidence Program. U.S. Food and Drug Administration. Accessed May 5, 2023. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-real-world-evidence-program
  • Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023 Feb;11(2):e005344. doi: 10.1136/jitc-2022-005344. PubMed 36796877 ↗
  • Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3. PubMed 29968853 ↗
  • Grayson N. Real-world data can help make better drugs and do it faster. STAT. Published May 2, 2018. Accessed May 5, 2023. https://www.statnews.com/2018/05/02/real-world-data-drug-development/
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2034, 106 months after the start.

Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's planned 106 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 4, 2025
StartActual
Jan 27, 2026
Primary completionEst.
Nov 2034
CompletionEst.
Nov 2035
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • University of Rochester · Rochester, United States
  • Sanford Fargo · Fargo, United States
  • Sanford Sioux Falls · Sioux Falls, United States
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    3 sites added
    Show 3 added (3 United States)
    • University of Rochester · Rochester, United States
    • Sanford Fargo · Fargo, United States
    • Sanford Sioux Falls · Sioux Falls, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07154823
Lead sponsor
Tempus AI
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Jan 27, 2026
Primary completion
Nov 2034 (estimated)
Completion
Nov 2035 (estimated)
Last update
Oct 9, 2026

Study contacts

Aquarius Clinical Study Manager
Contact
aquarius@tempus.com
800-739-4137
Michael Thompson, MD, PhD, FASCO
principal investigator · Tempus AI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion